Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Announces NanoBUP™ Capsule for Treating Opiate Addiction Demonstrated Bioavailability and Safety in Phase Ia Clinical Trial

Business Wire - August 2009

NanoBUP™ Oral Buprenorphine / Naloxone Capsule, for treating opiate addiction, demonstrated strong oral absorption in a Phase Ia clinical trial. The 2 x 2mg capsule achieved significant oral bioavailability of 60 to 70 percent, in comparison to sublingual administration of buprenorphine/naloxone at a similar dose, as reported in published scientific reports.

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.